Harnessing the power of KISIMA^® immunisation technology to discover and develop therapeutic vaccines

A novel approach to therapeutic vaccines

AMAL aims to tackle the obstacles for effective anti-cancer therapy by stimulating a patient’s immune system in a unique way.

More about AMAL

First-in-class immunisation technology

KISIMA^®, our unique proprietary protein-based immunisation platform is self-adjuvanting and delivers several antigens in one single vaccine.

More about KISIMA^®

Transforming the prospects of cancer patients

We focus on the development of viable effective cancer therapies. Our most advanced asset is ATP128, a therapeutic vaccine for the treatment of metastatic colorectal cancers.

More about portfolio

Latest

News

25 Jun 2020

AMAL Therapeutics SA announces the appointment of Dr. Thomas Bogenrieder as Chief Clinical Officer
15 Jul 2019

Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform
02 May 2019

AMAL Therapeutics enters clinical collaboration with Boehringer Ingelheim to evaluate ATP128 in combination with BI754091

Events

Meet with the AMAL Team soon!